Some statements contained on this Web Site are forward-looking with respect to our operations, economic performance, and financial condition. Statements that are forward-looking in nature should be read with caution because they involve risks and uncertainties. These forward-looking statements are included, for example, in specific and general discussions about Sangamo’s research and development of ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform, achievement of research milestones and objectives, strategic partnership and commercial license agreements with collaborators, presentation of data from research collaboration, expected timing for clinical trial data, anticipated cash resources, business strategies and any other statements that are not historical facts. Actual results may differ materially from those expressed or implied in those statements due to a number of factors, including the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, the ability to establish strategic partnerships, technological challenges, and technological developments by our competitors. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable therapeutics . For further discussion, please see the "Risk Factors" in Sangamo’s Annual Report on Form 10-K and our most recent 10-Q as filed with the Securities and Exchange Commission. Sangamo undertakes no obligation to publicly release any revisions to forward-looking statements to reflect events or circumstances arising after the date thereof.